Hemocompatibility-related adverse events in patients supported with magnetic levitated LVAD (HM3) vs Axial Flow LVAD (HMII) based on MOMENTUM 3 data at 2 and 5 years
| . | Heartmate II . | Heartmate 3 . | P value . |
|---|---|---|---|
| Strokes 2 y | 0.07 | 0.04 | .008 |
| Strokes 5 y | 0.136 | 0.05 | <.001 |
| Other neurologic events | 0.073 | 0.065 | .49 |
| Pump thrombosis 5 y | 0.108 | 0.010 | <.001 |
| Bleeding at 5 y | |||
| Any | 0.765 | 0.430 | <.001 |
| GIB | 0.423 | 0.252 | <.001 |
| . | Heartmate II . | Heartmate 3 . | P value . |
|---|---|---|---|
| Strokes 2 y | 0.07 | 0.04 | .008 |
| Strokes 5 y | 0.136 | 0.05 | <.001 |
| Other neurologic events | 0.073 | 0.065 | .49 |
| Pump thrombosis 5 y | 0.108 | 0.010 | <.001 |
| Bleeding at 5 y | |||
| Any | 0.765 | 0.430 | <.001 |
| GIB | 0.423 | 0.252 | <.001 |
Incidence are expressed in terms of EPPY. Data summarized in this table are obtained from the MOMENTUM 3 clinical trials.37,91
GIB, gastrointestinal bleeding.